The quick uptake of tailored therapies by stakeholders in Europe offers the opportunity to propel the Continent ahead of the US to reap commercial success, believes Jurgi Camblong.
Like most sectors, pharma periodically discovers new buzzwords and hot topics which become inescapable for 2-3 years, and begin to sound like the answer to every question.